Text
In collaboration with Queensland University of Technology, Microbio developed the InfectID™-BSI assay, a breakthrough diagnostic tool that identifies bloodstream infection pathogens in under three hours, dramatically reducing treatment delays for sepsis patients.
The company’s diagnostic portfolio also includes InfectID™-COVID-19 tests, which gained European regulatory clearance and international market recognition. Through strategic partnership with DMTC Limited, Microbio is enhancing Australia’s health security infrastructure and industrial capabilities. With plans to expand across human healthcare, agriculture, animal health and environmental surveillance, Microbio is positioning Queensland at the forefront of rapid diagnostic solutions to address emerging global health challenges.
The company’s diagnostic portfolio also includes InfectID™-COVID-19 tests, which gained European regulatory clearance and international market recognition. Through strategic partnership with DMTC Limited, Microbio is enhancing Australia’s health security infrastructure and industrial capabilities. With plans to expand across human healthcare, agriculture, animal health and environmental surveillance, Microbio is positioning Queensland at the forefront of rapid diagnostic solutions to address emerging global health challenges.
